In line with or results, Zadra et al. 12 showed that the novel AMPK direct activator MT63–78 inhibited LNCaP prostate tumor growth in vivo and promoted AMPK activation in xenograft tumors. Here, PRKAA2 is linked to prostate neoplasm.